SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SteadyMed Ltd. - STDY

NEW YORK, Aug. 31, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SteadyMed Ltd. ("SteadyMed" or the "Company") (NASDAQ:  STDY).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether SteadyMed and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On August 31, 2017, SteadyMed announced receipt of a Refusal to File letter from the U.S. Food and Drug Administration ("FDA") concerning the Company's New Drug Application ("NDA") for Treyvent, a pulmonary arterial hypertension treatment.  Based on a preliminary review of the NDA, which was submitted in June 2017, the FDA determined that the application is not sufficiently complete to permit a substantive review. 

On this news, SteadyMed's share price has fallen as much as $2.65, or 44.92%, during intraday trading on August 31, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-steadymed-ltd---stdy-300512446.html

SOURCE Pomerantz LLP